Quantcast

Latest Monoclonal antibodies Stories

2014-04-16 08:32:44

U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia, April 16, 2014 /PRNewswire/ -- Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top-tier U.S.-based institutional investors Farallon Capital Management, LLC, Adage Capital Partners, L.P, Foresite Capital, and Tavistock Life Sciences...

2014-04-11 08:24:18

LONDON, April 11, 2014 /PRNewswire/ -- ThioBridge(TM) linker to attach different payloads to a range of antibodies PolyTherics Limited ("PolyTherics"), a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge(TM) antibody drug conjugate ("ADC") collaboration with MacroGenics Inc (NASDAQ: MGNX), a US biotechnology company developing innovative medicines utilizing its next...

2014-04-10 08:29:30

MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a milestone payment from Merck, through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb® antibody...

2014-04-10 08:28:53

NEW YORK, April 10, 2014 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic...

2014-04-08 08:32:31

Additional preclinical data highlights the pharmacologic properties of PEGPH20 SAN DIEGO, April 8, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the American Association for Cancer Research (AACR) annual meeting being held in San Diego. The first presentation includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of...

2014-04-07 04:21:25

BREDA, The Netherlands and GHENT, Belgium, April 7, 2014 /PRNewswire/ -- New findings to be presented at the American Association for Cancer Research annual meeting arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody(TM) platform has identified four 'hotspots' on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET...

2014-04-04 16:23:39

TARRYTOWN, N.Y., April 4, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has elected Robert A. Ingram to its Board of Directors. Regeneron also announced that Dr. Eric Shooter, a co-founder of the Company, is retiring from the Board after nearly 26 years of service to Regeneron. Mr. Ingram was nominated to become a member of Regeneron's Board by Sanofi. Under the terms of an investor agreement between Regeneron and Sanofi, Sanofi...

2014-04-03 20:22:32

SOUTH SAN FRANCISCO, Calif., April 3, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conference: -- 13(th) Annual Needham Healthcare Conference Tuesday, April 8, 2014 at the Westin Grand Central Hotel in New York City, NY 11:20AM - 11:50AM US ET (8:20AM - 8:50AM US PT) Presentations will include overviews of the company's KB001-A development program to...

2014-04-03 08:29:04

-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE, April 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement?mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2),...

2014-04-03 04:20:52

CAMBRIDGE, England, April 3, 2014 /PRNewswire/ -- GBP19.5M raised to drive development of best-in-class fully human VH antibody fragment therapeutics Crescendo Biologics Limited (Crescendo) today announces it has raised a further GBP2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals GBP19.5m. It was led by Imperial Innovations and included new...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.